Cerivastatin-d3 (sodium)

Cerivastatin-d3 sodium is deuterated labeled Cerivastatin sodium (HY-109523) . Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect[1][2].

Product Specifications

CAS Number

[916314-45-9]

UNSPSC

12352005

Target

Ferroptosis; HMG-CoA Reductase (HMGCR) ; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Solubility

10 mM in DMSO

Smiles

FC(C=C1)=CC=C1C2=C(/C=C/[C@@H](O)C[C@@H](O)CC(O[Na])=O)C(C(C)C)=NC(C(C)C)=C2COC([2H])([2H])[2H]

Molecular Formula

C26H30D3FNNaO5

Molecular Weight

484.55

References & Citations

[1]Denoyelle C, et al. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis. 2001 Aug;22 (8) :1139-48.|[2]Stein E, et al. Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia. J Cardiovasc Pharmacol Ther. 1997 Jan;2 (1) :7-16.|[3]Furberg CD, et al. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med. 2001;2 (5) :205-207.|[4]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.